Altimmune(us:ALT)
5.00
-6.02%
Updated on 2025-03-31
Open:5.07
Close:5.00
High:5.12
Low:4.78
Prev Close:5.32
Volume:3.59M
Turnover:17.74M
Turnover Ratio:4.67%
Shares:77.01M
MarketCap:385.07M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 205 | 42295612 | 59.53% | 45 | 51 | 81 |
| 2024-03-31 | 193 | 44354387 | 62.56% | 56 | 50 | 66 |
| 2023-12-31 | 166 | 33501373 | 47.40% | 54 | 41 | 50 |
| 2023-09-30 | 134 | 30302743 | 57.33% | 17 | 27 | 63 |
| 2023-06-30 | 160 | 35238005 | 66.92% | 28 | 39 | 74 |
| 2023-03-31 | 163 | 43405534 | 88.07% | 36 | 51 | 62 |
| 2022-12-31 | 160 | 46818490 | 95.16% | 36 | 38 | 67 |
| 2022-09-30 | 147 | 46034561 | 93.64% | 39 | 39 | 53 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Blackrock Inc. | 5321089 | 7.49% | 1278863 | 31.64% |
| 2024-06-30 | Vanguard Group Inc | 4906614 | 6.91% | 1777886 | 56.83% |
| 2024-06-30 | State Street Corp | 3909286 | 5.50% | -4739984 | -54.80% |
| 2024-06-30 | Ameriprise Financial Inc | 3223997 | 4.54% | 1514693 | 88.61% |
| 2024-06-30 | Tang Capital Management Llc | 2750000 | 3.87% | 0 | |
| 2024-06-30 | Susquehanna International Group, Llp | 2210401 | 3.11% | 1294147 | 141.24% |
| 2024-06-30 | Geode Capital Management, Llc | 1593810 | 2.24% | 357012 | 28.87% |
| 2024-06-30 | Morgan Stanley | 1291020 | 1.82% | -920928 | -41.63% |
| 2024-06-30 | Knoll Capital Management, Llc | 1121524 | 1.58% | 554305 | 97.72% |
| 2024-06-30 | Goldman Sachs Group Inc | 1010149 | 1.42% | 148734 | 17.27% |
About
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Address:910 Clopper Road,Suite 201S
Website:http://www.altimmune.com
Market Movers